Molecular Mechanisms of Aneurysmal Degeneration
动脉瘤变性的分子机制
基本信息
- 批准号:6973707
- 负责人:
- 金额:$ 34.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-08-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
Abdominal aortic aneurysms (AAAs) are a common and life-threatening condition. The goal of this project is to elucidate cellular and molecular mechanisms responsible for aortic wall degeneration using a mouse model of elastase-induced AAAs previously characterized in our laboratory. This model recapitulates many critical features of human AAAs, including transmural infiltration of the aortic wall by rnononuclear phagocytes, increased local production of proinflammatory cytokines and matrix metalloproteinases (MMPs). and progressive degradation of elastin and collagen. We have shown that targeted deletion of MMP-9 inhibits elastase-induced AAAs with suppression of elastin degradation, whereas AAAs are enhanced in the absence of the endogenous MMP inhibitor, TIMP-1. Because we found even greater enhancement of AAAs in mice lacking both MMP-9 and TIMP-1, more detailed knowledge is needed regarding the in vivo interactions between MMP-9, TIMP-1, and other elastolytic MMPs, and the specific role of MMP-9 in aortic elastin degradation. It is also important to consider if altered susceptibility to AAAs will occur in mice with resistance to collagenase-mediated degradation of interstitial collagen or in mice lacking expression of coilagenase-3 (MMP-13), one of the principal MMP-collagenases. Because we have observed suppression of elastase-induced AAAs in mice with targeted deletion of cathepsin-S (Cst-S), an elastolytic and collagenolytic cysteine protease, the mechanisms by which Cat-S promotes aneurysmal degeneration also need to be defined. These issues will be addressed by accomplishing the following three specific aims: (1) Clarify how MMP-9, TIMP-1 and other elastolytic MMPs influence the development of eiastase-induced AAAs, if MMP-9 is directly responsible for aortic wall elastin degradation in vivo, and if matrilysin (MMP-7) is required for aneurysmal degeneration; (2) Establish if MMP-mediated degradation of interstitial (type I) collagen is required in the development of experimental AAAs and if MMP-13 is essential in this process; and (3) Identify the functionally important cellular sources of Cat-S during the development of elastaseinduced AAAs and the molecular mechanisms by which targeted gene deletion of Cat-S suppresses aneurysmal degeneration. Taken together, these studies will contribute important new information on the mechanisms underlying extracellular matrix degradation in aneurysmal degeneration.
描述(由申请人提供):
腹主动脉瘤(AAA)是一种常见且危及生命的疾病。本项目的目的是阐明细胞和分子机制,负责主动脉壁变性使用弹性蛋白酶诱导的AAAs小鼠模型先前在我们的实验室的特点。该模型概括了人AAA的许多关键特征,包括单核巨噬细胞对主动脉壁的透壁浸润,促炎细胞因子和基质金属蛋白酶(MMP)的局部产生增加。以及弹性蛋白和胶原蛋白的逐渐降解。我们已经表明,有针对性地删除MMP-9抑制弹性蛋白酶诱导的AAAs与抑制弹性蛋白降解,而AAAs增强的内源性MMP抑制剂,TIMP-1的情况下。因为我们发现在缺乏MMP-9和TIMP-1的小鼠中AAA的增强更大,所以需要关于MMP-9,TIMP-1和其他弹性蛋白溶解MMP之间的体内相互作用以及MMP-9在主动脉弹性蛋白降解中的特定作用的更详细的知识。同样重要的是要考虑是否会改变对AAA的敏感性将发生在对胶原酶介导的间质胶原降解具有抗性的小鼠中或在缺乏胶原酶-3(MMP-13)(主要MMP-胶原酶之一)表达的小鼠中。因为我们已经观察到在靶向缺失组织蛋白酶-S(Cst-S)(一种弹性蛋白溶解和胶原溶解半胱氨酸蛋白酶)的小鼠中抑制弹性蛋白酶诱导的AAA,所以还需要确定Cat-S促进囊性变性的机制。(1)阐明MMP-9、TIMP-1和其他弹性蛋白溶解性MMP如何影响弹性蛋白酶诱导的AAA的发展,MMP-9是否直接负责体内主动脉壁弹性蛋白降解,以及基质溶解素(MMP-7)是否是血管平滑肌变性所必需的;(2)确定MMP介导的间质(I型)胶原的降解是否在实验性AAA的发展中是必需的,以及MMP-13是否在该过程中是必需的;(3)确定Cat-S在弹性蛋白酶诱导的AAAs形成过程中的重要功能细胞来源以及Cat-S靶向基因缺失抑制AAAs变性的分子机制。总之,这些研究将有助于重要的细胞外基质降解的机制,在垂体退行性变的新信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert W. Thompson其他文献
Long-term effectiveness of extraanatomic renal artery revascularization.
解剖外肾动脉血运重建的长期有效性。
- DOI:
- 发表时间:
1994 - 期刊:
- 影响因子:3.8
- 作者:
J. Reilly;B. Rubin;Robert W. Thompson;Brent T. Allen;Charles B. Anderson;Gregorio A. Sicard;Thomas W. Wakefield;M. Tsapogas;F. O. Belzer;W. Turnipseed;R. Pollak - 通讯作者:
R. Pollak
Therapeutische residentiële hulp voor kinderen en jongeren: een consensusverklaring van de Internationale Werkgroep Therapeutische Residentiële Zorg
Therapeutische Residentiële hulp voor kinderen en jongeren: een consensusverklaring van de Internationale Werkgroep Therapeutische Residentiële Zorg
- DOI:
- 发表时间:
2016 - 期刊:
- 影响因子:0
- 作者:
James K. Whittaker;Lisa Holmes;Jorge F. del Valle;Frank Ainsworth;Tore Andreassen;James P. Anglin;Christopher Bellonci;D. Berridge;Amaia Bravo;Cinzia Canali;Mark E. Courtney;Laurah Currey;Daniel L. Daly;Robbie Gilligan;H. Grietens;A. Harder;Martha J. Holden;S. James;Andrew Kendrick;E. Knorth;Mette Lausten;John S. Lyons;Eduardo Martín;Samantha McDermid;Patricia McNamara;Laura Palareti;Susan Ramsay;Kari M. Sisson;Richard W. Small;June Thoburn;Robert W. Thompson;Anat Zeira - 通讯作者:
Anat Zeira
The Supraclavius Muscle: A Novel Muscular Anomaly Crossing the Supraclavicular Space Observed in Two Cases of Thoracic Outlet Syndrome
- DOI:
10.1016/j.jvs.2014.07.082 - 发表时间:
2014-10-01 - 期刊:
- 影响因子:
- 作者:
Payam Salehi;Wande Pratt;Michael F. Joseph;Lauren N. McLaughlin;Robert W. Thompson - 通讯作者:
Robert W. Thompson
The environmental regulator and industrial development
- DOI:
10.1007/bf01866804 - 发表时间:
1982-01-01 - 期刊:
- 影响因子:3.000
- 作者:
Robert W. Thompson;Charles F. Harding - 通讯作者:
Charles F. Harding
Evaluation and Management of Venous Thoracic Outlet Syndrome.
胸廓静脉出口综合征的评估和治疗。
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:2.1
- 作者:
J. Cook;Robert W. Thompson - 通讯作者:
Robert W. Thompson
Robert W. Thompson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert W. Thompson', 18)}}的其他基金
SMOOTH MUSCLE CELL SENESCENCE IN AORTIC ANEURYSMS
主动脉瘤中的平滑肌细胞衰老
- 批准号:
2406968 - 财政年份:1997
- 资助金额:
$ 34.43万 - 项目类别:
相似海外基金
Prevention of age-related hearing loss using bone marrow transplantation
利用骨髓移植预防与年龄相关的听力损失
- 批准号:
23K08999 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
- 批准号:
2889841 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Studentship
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
- 批准号:
10737358 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10722602 - 财政年份:2022
- 资助金额:
$ 34.43万 - 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
- 批准号:
10368246 - 财政年份:2022
- 资助金额:
$ 34.43万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10600143 - 财政年份:2022
- 资助金额:
$ 34.43万 - 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
- 批准号:
10370775 - 财政年份:2022
- 资助金额:
$ 34.43万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10415200 - 财政年份:2021
- 资助金额:
$ 34.43万 - 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
- 批准号:
10303678 - 财政年份:2021
- 资助金额:
$ 34.43万 - 项目类别: